ACXP - Multiplikator Forward P/S Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals (ACXP) automates antibiotic discovery through computer modeling, optimizing its scientific staff. The forward P/S multiple visualizes the long-term valuation trend, where the indicator expresses the state of the metric. A focus on Phase II trials for new drugs, combined with low production costs and patent protection, creates potential for pricing power following FDA approval.

This metric compares the current market value of Acurx Pharmaceuticals (ACXP) with expected sales volume, reflecting the premium the market is willing to pay for future cash flows. By analyzing the forward price-to-sales ratio, an investor assesses the fairness of the company's valuation considering the stability of antibiotic substance supplies, where an increase in the metric confirms confidence in the margins of drug development.